Championing diversity and inclusion in neuro-oncology
Explore opportunities for women in neuro-oncology with Dr Macarena Ines De La Fuente who has been the co-chair of the SNO’s Women and Diversity Committee.
Explore opportunities for women in neuro-oncology with Dr Macarena Ines De La Fuente who has been the co-chair of the SNO’s Women and Diversity Committee.
A phase Ib study established the recommended phase II dose of oral unesbulin in combination with dacarbazine for patients with locally recurrent, unresectable or metastatic,…
Fred Hutch virologists eliminated at least 90% of HSV-1 in preclinical models of oral and genital herpes and reduced viral shedding in a study published…
The American Association for Cancer Research named Nickolas Papadopoulos as editor-in-chief of Cancer Prevention Research, one 10 journals published by the AACR. To access this…
AbstractTherapeutic approaches for clear cell renal cell carcinoma (ccRCC) remain limited; however, chimeric antigen receptor (CAR) T-cell therapies may offer novel treatment options. CTX130, an…
Ariel Lopez-Chavez, MD, emphasizes the critical need for improved second-line therapies in small cell lung cancer.
Circulating multilymphoid progenitors are primed for the seeding the thymus and contribute to steady-state T-cell lymphopoiesis.cHSPCs are responsible for
Researchers sought to determine the correlation between patient-reported physical function and objective physical function measures.
Samilia Obeng-Gyasi, MD, MPH, expands on the impact of social determinants of health on breast cancer care.
In case you missed it, below is your guide to the important regulatory approvals made by the FDA in April 2024.
For more than 70 years, glucocorticoids have been known to have clinical activity against lymphoid but not myeloma malignancies. Choi et al. resolve this conundrum by…